- Cediranib
drugbox
IUPAC_name = 4- [(4-fluoro-2-methyl-1"H"-indol-5-yl)oxy] -6-methoxy-
7- [3-(pyrrolidin-1-yl)propoxy] quinazoline
CAS_number =
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C = 25 | H = 27 | F = 1 | N = 4 | O = 3
molecular_weight = 450.5 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 12 to 35 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = OralCediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of
vascular endothelial growth factor (VEGF) receptortyrosine kinase s. It is being developed byAstraZeneca as a possible chemotherapeutic agent for oral administration.As of 2007, it is undergoing Phase I
clinical trial s for the treatment of non-small celllung cancer andcolorectal cancer in adults, as well as tumors of thecentral nervous system in children.On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
Further reading
*cite journal |author=Wedge S, Kendrew J, Hennequin L "et al". |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res |volume=65 |issue=10 |pages=4389–400 |year=2005 |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409
External links
* [http://www.cancerline.com/cancerlinehcp/15602_15632_9_3_1.aspx AZD2171—AstraZeneca Pipeline]
Wikimedia Foundation. 2010.